Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Healthy Japanese Volunteers Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

NCT00788294

View directory record Official record

Conditions: Healthy Volunteers
Interventions: tanezumab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Oct 5, 2020 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

NCT00741689

View directory record Official record

Conditions: Healthy Volunteers
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 40 Years · Male only

Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Dec 2, 2010 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

NCT00551317

View directory record Official record

Conditions: Atherosclerosis
Interventions: Darapladib (SB480848); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 64 Years · Male only

Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Honolulu, Hawaii

Source: ClinicalTrials.gov public record

Updated Dec 4, 2016 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

NCT01167868

View directory record Official record

Conditions: Healthy
Interventions: FosD, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years

Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Feb 6, 2013 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

NCT06411730

View directory record Official record

Conditions: Healthy Participants
Interventions: BMS-986368; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Nov 11, 2024 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects

NCT01258777

View directory record Official record

Conditions: Healthy Volunteers
Interventions: 400 mg golimumab or placebo, 200 mg golimumab or placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only

Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Sep 3, 2013 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

NCT04052360

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Cenerimod, Matching Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 65 Years · Male only

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Sep 21, 2025 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

NCT03310021

View directory record Official record

Conditions: Bleeding
Interventions: Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Feb 23, 2023 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

NCT03188783

View directory record Official record

Conditions: Healthy Volunteer
Interventions: GDC-0853, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Aug 6, 2019 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

NCT06722417

View directory record Official record

Conditions: Healthy Volunteer
Interventions: Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Jan 27, 2025 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

NCT01105780

View directory record Official record

Conditions: Healthy
Interventions: Placebo, JNJ-41443532; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Apr 7, 2014 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects

NCT00912353

View directory record Official record

Conditions: Healthy
Interventions: AZD7268, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years

Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Gelndale, California

Source: ClinicalTrials.gov public record

Updated Jan 28, 2013 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

NCT00785915

View directory record Official record

Conditions: Healthy
Interventions: AZD6765, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years

Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Oct 12, 2014 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790

View directory record Official record

Conditions: Healthy Subjects
Interventions: E2609, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years to 60 Years · Male only

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Nov 2, 2015 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

NCT02516618

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 20 Years to 55 Years

Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated May 11, 2016 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

NCT03146416

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Evinacumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Jun 24, 2018 · Synced May 22, 2026, 3:50 AM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

NCT07525947

View directory record Official record

Conditions: Healthy Volunteers (HV)
Interventions: JADE101; Drug
Lead sponsor: Jade Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants

NCT07133191

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Selatogrel, Matching placebo; Combination Product
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 20 Years to 65 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Dec 15, 2025 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects

NCT01368926

View directory record Official record

Conditions: Healthy Volunteer
Interventions: RO4917523, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Nov 1, 2016 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

NCT00653822

View directory record Official record

Conditions: Pharmacokinetics of Alefacept
Interventions: alefacept, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 20 Years to 65 Years

Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Feb 27, 2013 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers

NCT05249348

View directory record Official record

Conditions: Healthy Volunteers
Interventions: PC14586; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Nov 12, 2024 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

NCT05305222

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Risankizumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 45 Years · Male only

Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Mar 30, 2022 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

NCT04079101

View directory record Official record

Conditions: Healthy Volunteers
Interventions: BIIB104, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years · Male only

Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Source: ClinicalTrials.gov public record

Updated Mar 23, 2021 · Synced May 22, 2026, 3:50 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

NCT01618916

View directory record Official record

Conditions: Healthy Volunteers
Interventions: LY3015014, Placebo; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Honolulu, Hawaii • Dallas, Texas

Source: ClinicalTrials.gov public record

Updated Mar 14, 2019 · Synced May 22, 2026, 3:50 AM EDT